Biologics Treatment Selection in Patients With Moderate-to-Severe Asthma

Andrew White, MD, provides an overview of the difference of asthma endotypes and phenotypes as a way to define and diagnose asthma.

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, describes the mechanism of type 2 inflammation and comments on it being a prominent issue among patients with asthma.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the symptoms of coughing, wheezing, and shortness of breath as a product of an overactive immune system and as a sign of asthma.

A panel of experts comment on primary care vs specialist care for patients with asthma, and when patients should be referred to a specialist.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the tools available to predict the exacerbation of asthma, highlighting spirometry and biomarkers as effective tools

Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.

Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.

Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.

Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.

Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.

Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.

Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.

Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.

Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.

Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI; Dareen D. Siri, MD, FAAAAI, FACAAI; Nicole Chase, MD, FAAP, FACAAI, FAAAAI; and Andrew White, MD, give final thoughts on asthma management, considering the current treatment landscape.